title: Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances.
abstract: Despite significant advancements in the treatment and outcome of hematologic malignancies, prognosis remains poor for patients who have relapsed or refractory disease. Adoptive T-cell immunotherapy offers novel therapeutics that attempt to utilize the noted graft versus leukemia effect. While CD19 chimeric antigen receptor (CAR)-modified T cells have thus far been the most clinically successful application of adoptive T immunotherapy, further work with antigen specific T cells and CARs that recognize other targets have helped diversify the field to treat a broad spectrum of hematologic malignancies. This article will focus primarily on therapies currently in the clinical trial phase as well as current downfalls or limitations.
authors.affiliation: Children's National Health System and The George Washington University, Washington, DC, USA.
authors.forename: Lauren
authors.initials: L
authors.lastname: McLaughlin
authors.affiliation: Children's National Health System and The George Washington University, Washington, DC, USA.
authors.forename: C Russell
authors.initials: CR
authors.lastname: Cruz
authors.affiliation: Children's National Health System and The George Washington University, 111 Michigan Ave, Washington, DC 20010, USA.
authors.forename: Catherine M
authors.initials: CM
authors.lastname: Bollard
keywords: antigen-specific T cells; chimeric antigen receptor; cytotoxic T lymphocytes; immunotherapy